LONDON, August 14, 2025 (ITIA Press Release)

The International Tennis Integrity Agency (ITIA) today confirms that Australian tennis player Thomas Fancutt has accepted a suspension of 10 months under the Tennis Anti-Doping Programme (TADP).

30-year-old Fancutt, who reached a career-high world doubles ranking of 107 in December 2024, admitted to breaching Article 2.2 of the TADP (use of a Prohibited Method) by receiving an intravenous infusion over the accepted limit on 3 December 2024. The limit under the World Anti-Doping Code (WADC) and TADP is 100mL in a 12-hour period.

The ITIA sent the player a notice of a potential Anti-Doping Rule Violation (ADRV) on 7 March 2025. On 19 March 2025, the player requested to enter into a voluntary provisional suspension, which came into effect immediately.

Following a full investigation by the ITIA, which included evidence gathering and interviews with the player, Fancutt admitted to the breach, and the ITIA accepted that the breach was not intentional.

In determining sanction, the ITIA considered relevant precedents across all WADC-compliant sports, in addition to the player’s early admission and full co-operation.

Time served under the voluntary provisional suspension is credited against the period of ineligibility. As such, Fancutt’s suspension will end on 18 January 2026. The player will also forfeit results and prize money from the date of their first ADRV (3 December 2024) to their first subsequent negative doping control sample, which was provided on 16 January 2025.

During the period of ineligibility, Fancutt is prohibited from playing in, coaching at, or attending any tennis event authorised or sanctioned by the members of the ITIA (ATP, ITF, WTA, Tennis Australia, Fédération Française de Tennis, Wimbledon and USTA) or any national association.